Skip to content

Colloid Preload Versus Colloid Coload During Cesarean Deliveries

Colloid Preload Versus Colloid Coload in Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Section Deliveries: A Prospective, Randomized, Double-Blind Comparative Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02393196
Enrollment
200
Registered
2015-03-19
Start date
2015-03-31
Completion date
2016-03-31
Last updated
2015-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia; Adverse Effect, Spinal and Epidural, Hypotension

Keywords

colloid preloading, colloid coloading

Brief summary

The investigators aimed to compare the methods colloid preloading and colloid coloading in terms of the incidence of maternal hypotension and impacts on neonatal outcomes. The second aim while planning the present study is to identify the method of the lowest adverse event for mother and infant and the simplest approach for the clinician.

Detailed description

Spinal anesthesia (SA) is currently the most preferred method of anesthesia in elective cesarean deliveries. However, SA causes maternal hypotension by decreasing systemic vascular resistance over sympathetic blockade. Maternal hypotension can lead to serious adverse events both in mother and in fetus: fetal hypoxia and acidosis occur due to decreased uterine blood flow, whereas the mother may experience vertigo, nausea, vomiting, alteration in consciousness, cardiovascular collapse and arrest. Today, various strategies have been suggested for the prevention of maternal hypotension. Of these strategies, the most critical ones are fluid load before spinal anesthesia (preloading) or rapid fluid load just after spinal anesthesia (coloading) and the use of vasopressor agent. The fluids used for this purpose include crystalloids and colloids. Comparative studies performed with colloid preloading, colloid coloading and crystalloid coloading indicated that the incidence of hypotension decreased similarly with no significant difference determined between the methods of fluid loading. Researchers defended necessity of using vasopressor agent together with fluid loading methods. In daily routine; however, the investigators observe that the incidence of hypotension is lower in the patients that undergo colloid preloading as compared to the patients that undergo colloid coloading or crystalloid coloading. The investigators therefore aimed to compare the methods colloid preloading and colloid coloading in terms of the incidence of maternal hypotension and impacts on neonatal outcomes. In the present study, the investigators aimed to use 6% HES 130/0.4 (Voluven ®), which is the newer generation colloid solution. The other aim while planning the present study is to identify the method of the lowest adverse event for mother and infant and the simplest approach for the clinician.

Interventions

DRUGhydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)

Before spinal anesthesia

DRUGhydroxyethyl starch (%6 HES 130/0.4) (Voluven®)

Just after spinal anesthesia

Sponsors

Sifa University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 18 years or older * Singleton pregnancy * Gestational age ≥ 37 weeks * Height ≥ 150 cm and ≤ 180 cm * Weight \> 50 kg and \< 100 kg

Exclusion criteria

* Gestational age \> 37 weeks * Multiple pregnancies * Fetal distress * Preeclampsia * Cardiovascular disease and diabetes * Hematological problems * Local infection at intervention site * Abnormal coagulation tests * Anticoagulant use * Starch allergy * Height \< 150 cm and \> 180 cm * Weight \< 50 kg and \> 100 kg

Design outcomes

Primary

MeasureTime frameDescription
Cumulative duration of hypotension.Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.Cumulative duration of hypotension will be recorded from induction of spinal anesthesia until delivery (umbilical cord clamping).
Incidence of severe hypotension.Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.Incidence of severe hypotension (SAP \< 70% of the baseline value or SAP \< 80 mmHg) will be recorded.
Maternal hypotension.Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.Maternal hypotension will be defined as at least a single administration of ephedrine within the period from induction of SA to the delivery (umbilical cord clamping). After spinal anesthesia, SAP will be measured and recorded at every minute until birth and every three minutes thereafter.
Heart rate.Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.Minimum and maximum heart rate, bradycardia, atropine usage will be recorded.

Secondary

MeasureTime frameDescription
Nausea and/or vomiting.Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.Incidence of nausea and/or vomiting, incidence of prepartum nausea and/or vomiting will be recorded.
Neonatal effects.Time just after delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.Arterial and venous blood gas analyses will be performed from the umbilical cord after the cord clamped.
Ephedrine treatment.Time between induction of spinal anesthesia until delivery (umbilical cord clamping). Participants will be followed for the duration of hospital stay, an expected average of two days.If SAB \< 100 mmHg; patients will be treated by 5 mg IV bolus ephedrine, if SAB \< 90 mmHg; patients will be treated by 10 mg IV bolus ephedrine.

Other

MeasureTime frameDescription
Preoperative fasting period.Time before spinal anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days.preoperative fasting period will be recorded.
Durations of anesthesia and surgery.Time between induction of spinal anesthesia until end of the anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days.Time period from induction of spinal anesthesia to skin incision (min), time period from induction of spinal anesthesia to delivery (min), time period from uterine incision to birth (sec), duration of anesthesia (min), and duration of surgery (min) will be recorded.
Preoperative hemoglobin concentration (g/dL).Time before spinal anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days.Before spinal anesthesia. Participants will be followed for the duration of hospital stay, an expected average of two days.

Countries

Turkey (Türkiye)

Contacts

Primary ContactAysun Afife Kar, MD
aaysunkar@hotmail.com+905326521313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026